AndroGel: Clinical Trials

9 trials of AndroGel, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 unknown, 1 recruiting. 9 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 6, Unknown 2, Recruiting 1
Phase 21Completed 1

Follow AndroGel: new trials by email Literature Review of AndroGel trials Research Report on AndroGel

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
Testosterone gel, Placebo - Prostatic Neoplasms, Hypogonadism
Phase 3RecruitingCanisius-Wilhelmina Hospital1402022-12-122025-05-02
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study
Testosterone gel, Placebo - Disorder of Sex Development, 46,XY
Phase 3UnknownErasmus Medical Center12021-06-012021-04-05
Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort
Testosterone, Estradiol - Fertility Disorders
Phase 3UnknownHospital de Clinicas de Porto Alegre262017-08-012017-08-03
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
SOV2012-F1, AndroGel - Hypogonadism, Male
Phase 3CompletedMarius Pharmaceuticals3142017-07-052023-06-28
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Oral testosterone undecanoate, Transdermal testosterone gel (AndroGel) - Male Hypogonadism
Phase 3CompletedClarus Therapeutics, Inc.1822012-08-012021-06-28
PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
placebo acyline, placebo gel, Testosterone 1% gel 1.25 g - Healthy
Phase 2 / Phase 3CompletedUniversity of Washington622011-10-012017-10-05
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
Testosterone, Placebo - Advanced Cancer
Phase 3CompletedM.D. Anderson Cancer Center532009-09-012016-09-13
Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism
Androxal, AndroGel, Placebo - Secondary Hypogonadism
Phase 3CompletedRepros Therapeutics Inc.1942006-03-012010-02-11
Exercise and Testosterone Therapy in Elderly Men With Physical Frailty
Transdermal Testosterone gel (1%), Supervised exercise training - Physical Frailty, Hip Fracture
Phase 3CompletedWashington University School of Medicine252004-11-012018-02-22

Conditions studied

Hypogonadism (3)  ·  Eunuchism (2)  ·  Disorder of Sex Development, 46,XY (1)  ·  Fatigue (1)  ·  Hip Fractures (1)  ·  Neoplasms (1)  ·  Prostatic Neoplasms (1)

Sponsors

Canisius-Wilhelmina Hospital (1)  ·  Clarus Therapeutics, Inc. (1)  ·  Erasmus Medical Center (1)  ·  Hospital de Clinicas de Porto Alegre (1)  ·  M.D. Anderson Cancer Center (1)  ·  Marius Pharmaceuticals (1)  ·  Repros Therapeutics Inc. (1)  ·  University of Washington (1)  ·  Washington University School of Medicine (1)

Countries

United States (6)  ·  Netherlands (2)  ·  Germany (1)

Top investigators

Alastair Smith, MB, ChB (1)  ·  Andre van As, MD, PhD (1)  ·  Diederik Somford, MD, PhD (1)  ·  Ellen F. Binder, MD (1)  ·  Laura de Graaff, MD, PhD (1)  ·  Om Dhingra, PhD (1)  ·  Ronald Swerdloff, MD (1)  ·  Rony Dev, DO (1)  ·  Stephanie T Page, MD, PhD (1)

Results publications

PMID 27172434, PMID 36272969, PMID 38606384, PMID 40514343

NIH funding

R01AG037603 (1)